Evidence map›Paper›PMID 40017252›Full record

ReviewCurrent pharmaceutical design2025

Recent Advancement in Drug Targeting Therapies in the Treatment of Pancreatic Cancer.

Ranjit K Harwansh, Junainah Abd Hamid, Pranay Wal, Rohitas Deshmukh, Pratap Kumar Patra, Amin Gasmi

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current pharmaceutical design, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Ranjit K HarwanshDepartment of Pharmacy, Institute of Pharmaceutical Research, GLA University, Mathura, 281406, India.
Junainah Abd HamidDepartment of Pharmacy, Management and Science University, Shah Alam, Selangor, Malaysia.
Pranay WalDepartment of Pharmacy, Pranveer Singh Institute of Technology, Pharmacy, NH-19, Bhauti Road, Kanpur, 209305, India.
Rohitas DeshmukhDepartment of Pharmacy, Institute of Pharmaceutical Research, GLA University, Mathura, 281406, India.
Pratap Kumar PatraSchool of Pharmacy & Life Sciences, Centurion University of Technology & Management, Bhubaneswar, 752050, India.
Amin GasmiDepartment of Pharmacy, Société Francophone de Nutrithérapie et de Nutrigénétique Appliquée, Villeurbanne, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objective of the studyThis review aims to critically analyze the scope for targeting drugs towards the treatment of improving outcomes in PDAC, focusing on DNA repair inhibitors, antiangiogenic therapy, inhibitors of the KRAS pathway, anti-stromal, and nanoparticle-based therapy. MATERIALS AND

methodsA critical review of preclinical and clinical studies was conducted to summarize the therapeutic interventions that target specific mutations in PDAC, components of the tumor microenvironment, and drug delivery systems, especially nanotechnology, to enhance targeting and efficacy.

resultsInhibitors and nanotechnology-based targeted therapies have reported promise in preclinical models: drug delivery is enhanced with the loss of PDAC resistance mechanisms. Formulations and combinations targeting KRAS as well as other pathways point toward improved drug delivery over 'orthodox' treatment approaches.

conclusionThis review concludes that although improvement in therapies for PDAC has incrementally been proven in recent literature, however, more research is expected to enhance these approaches so that they can be applied appropriately at the clinical stage. In future studies, it is expected to optimize treatment combinations, address mechanisms of resistance, and improve the delivery of drugs.

Indexed as

Antineoplastic AgentsDrug Delivery SystemsMolecular Targeted TherapyPancreatic NeoplasmsAnimalsHumansTumor MicroenvironmentAntineoplastic AgentscancerfluorouracilKRAS pathway.PancreasPDACtargeted therapy

Identifiers

PMID40017252

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.